Open Access. Powered by Scholars. Published by Universities.®
Zucker School of Medicine at Hofstra/Northwell
Adolescent;; Advisory Committees;; Centers for Disease Control and Prevention (U.S.);; Child;; Humans;; Immunization/*standards;; Meningococcal Infections/epidemiology/*prevention & control;; Meningococcal Vaccines/*administration & dosage/adverse effects/immunology;; *Neisseria meningitidis
Articles 1 - 1 of 1
Full-Text Articles in Medicine and Health Sciences
Use Of Serogroup B Meningococcal Vaccines In Adolescents And Young Adults: Recommendations Of The Advisory Committee On Immunization Practices, 2015, J. R. Macneil, L. Rubin, T. Folaranmi, I. R. Ortega-Sanchez, M. Patel, S. W. Martin
Use Of Serogroup B Meningococcal Vaccines In Adolescents And Young Adults: Recommendations Of The Advisory Committee On Immunization Practices, 2015, J. R. Macneil, L. Rubin, T. Folaranmi, I. R. Ortega-Sanchez, M. Patel, S. W. Martin
Journal Articles
At its June 2015 meeting, the Advisory Committee on Immunization Practices (ACIP) recommended that adolescents and young adults aged 16-23 years may be vaccinated with a serogroup B meningococcal (MenB) vaccine to provide short-term protection against most strains of serogroup B meningococcal disease. This report summarizes the deliberations of ACIP, the rationale for its decision, and recommendations for use of MenB vaccines in adolescents and young adults. Two MenB vaccines have recently been licensed by the Food and Drug Administration (FDA) for use in the United States and approved for use in persons aged 10-25 years: MenB-FHbp (Trumenba, Wyeth Pharmaceuticals, …